Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

ParaDB: A manually curated database containing genomic annotation for the human pathogenic fungi Paracoccidioides spp.

Aciole Barbosa D, Menegidio FB, Alencar VC, Gonçalves RS, Silva JFS, Vilas Boas RO, Faustino de Maria YNL, Jabes DL, Costa de Oliveira R, Nunes LR.

PLoS Negl Trop Dis. 2019 Jul 15;13(7):e0007576. doi: 10.1371/journal.pntd.0007576. eCollection 2019 Jul.

2.

Bioportainer Workbench: a versatile and user-friendly system that integrates implementation, management, and use of bioinformatics resources in Docker environments.

Menegidio FB, Aciole Barbosa D, Gonçalves RDS, Nishime MM, Jabes DL, Costa de Oliveira R, Nunes LR.

Gigascience. 2019 Apr 1;8(4). pii: giz041. doi: 10.1093/gigascience/giz041.

3.

In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial.

Basilico N, Parapini S, Sparatore A, Romeo S, Misiano P, Vivas L, Yardley V, Croft SL, Habluetzel A, Lucantoni L, Renia L, Russell B, Suwanarusk R, Nosten F, Dondio G, Bigogno C, Jabes D, Taramelli D.

Molecules. 2017 Dec 1;22(12). pii: E2102. doi: 10.3390/molecules22122102.

4.

Expanding the potential of NAI-107 for treating serious ESKAPE pathogens: synergistic combinations against Gram-negatives and bactericidal activity against non-dividing cells.

Brunati C, Thomsen TT, Gaspari E, Maffioli S, Sosio M, Jabes D, Løbner-Olesen A, Donadio S.

J Antimicrob Chemother. 2018 Feb 1;73(2):414-424. doi: 10.1093/jac/dkx395.

5.

Dugong: a Docker image, based on Ubuntu Linux, focused on reproducibility and replicability for bioinformatics analyses.

Menegidio FB, Jabes DL, Costa de Oliveira R, Nunes LR.

Bioinformatics. 2018 Feb 1;34(3):514-515. doi: 10.1093/bioinformatics/btx554.

PMID:
28968637
6.

Functional and Evolutionary Characterization of a UDP-Xylose Synthase Gene from the Plant Pathogen Xylella fastidiosa, Involved in the Synthesis of Bacterial Lipopolysaccharide.

Alencar VC, Jabes DL, Menegidio FB, Sassaki GL, de Souza LR, Puzer L, Meneghetti MC, Lima MA, Tersariol IL, de Oliveira RC, Nunes LR.

Biochemistry. 2017 Feb 7;56(5):779-792. doi: 10.1021/acs.biochem.6b00886. Epub 2017 Jan 26.

PMID:
28125217
7.

Thioridazine inhibits gene expression control of the cell wall signaling pathway (CWI) in the human pathogenic fungus Paracoccidioides brasiliensis.

Jabes DL, de Freitas Oliveira AC, Alencar VC, Menegidio FB, Reno DL, Santos DS, Barbosa DA, Vilas Boas RO, de Oliveira Rodrigues Cunha RL, Rodrigues T, Costa de Oliveira R, Nunes LR.

Mol Genet Genomics. 2016 Jun;291(3):1347-62. doi: 10.1007/s00438-016-1184-1. Epub 2016 Mar 8.

PMID:
26956010
8.

Erratum for Jabes et al., Pharmacological Properties of NAI-603, a Well-Tolerated Semisynthetic Derivative of Ramoplanin.

Jabes D, Brunati C, Candiani G, Riva S, Romanó G, Maffioli S, Rossi R, Simone M, Gaspari E, Donadio S.

Antimicrob Agents Chemother. 2015 Oct;59(10):6675. doi: 10.1128/AAC.01526-15. No abstract available.

9.

A Derivative of the Thiopeptide GE2270A Highly Selective against Propionibacterium acnes.

Fabbretti A, He CG, Gaspari E, Maffioli S, Brandi L, Spurio R, Sosio M, Jabes D, Donadio S.

Antimicrob Agents Chemother. 2015 Aug;59(8):4560-8. doi: 10.1128/AAC.05155-14. Epub 2015 May 18.

10.

Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.

Sironi F, Malnati M, Mongelli N, Cozzi P, Guzzo C, Ghezzi S, Martínez-Romero C, García-Sastre A, Lusso P, Jabes D, Biswas P.

J Transl Med. 2015 Apr 2;13:107. doi: 10.1186/s12967-015-0461-9.

11.

Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin.

Jabes D, Brunati C, Candiani G, Riva S, Romanó G, Maffioli S, Rossi R, Simone M, Gaspari E, Donadio S.

Antimicrob Agents Chemother. 2014;58(4):1922-9. doi: 10.1128/AAC.01620-13. Epub 2014 Jan 13. Erratum in: Antimicrob Agents Chemother. 2015 Oct;59(10):6675.

12.

The antibiotic R&D pipeline: an update.

Jabes D.

Curr Opin Microbiol. 2011 Oct;14(5):564-9. doi: 10.1016/j.mib.2011.08.002. Epub 2011 Aug 26. Review.

PMID:
21873107
13.

Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.

Jabés D, Brunati C, Candiani G, Riva S, Romanó G, Donadio S.

Antimicrob Agents Chemother. 2011 Apr;55(4):1671-6. doi: 10.1128/AAC.01288-10. Epub 2011 Jan 10.

14.

Synthesis and anti-mycobacterial activities of triazoloquinolones.

Carta A, Palomba M, Briguglio I, Corona P, Piras S, Jabes D, Guglierame P, Molicotti P, Zanetti S.

Eur J Med Chem. 2011 Jan;46(1):320-6. doi: 10.1016/j.ejmech.2010.11.020. Epub 2010 Nov 19.

PMID:
21145625
15.

Sources of novel antibiotics--aside the common roads.

Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D.

Appl Microbiol Biotechnol. 2010 Dec;88(6):1261-7. doi: 10.1007/s00253-010-2877-8. Epub 2010 Sep 24. Review.

PMID:
20865256
16.

Antibiotic discovery in the twenty-first century: current trends and future perspectives.

Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D.

J Antibiot (Tokyo). 2010 Aug;63(8):423-30. doi: 10.1038/ja.2010.62. Epub 2010 Jun 16. Review.

PMID:
20551985
17.

Strategies for the isolation and characterization of antibacterial lantibiotics.

Jabes D, Donadio S.

Methods Mol Biol. 2010;618:31-45. doi: 10.1007/978-1-60761-594-1_3.

PMID:
20094856
18.

Synthesis and preliminary biological characterization of new semisynthetic derivatives of ramoplanin.

Ciabatti R, Maffioli SI, Panzone G, Canavesi A, Michelucci E, Tiseni PS, Marzorati E, Checchia A, Giannone M, Jabes D, Romano G, Brunati C, Candiani G, Castiglione F.

J Med Chem. 2007 Jun 28;50(13):3077-85. Epub 2007 Jun 2.

PMID:
17542573
19.

Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.

Freeman J, Baines SD, Jabes D, Wilcox MH.

J Antimicrob Chemother. 2005 Oct;56(4):717-25. Epub 2005 Sep 5.

PMID:
16143709
20.

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.

Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, White RJ, Henkel TJ.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii25-30. Review.

PMID:
15750034
21.

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D, Goldstein BP.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii21-4.

PMID:
15750033
22.
23.

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.

Jabés D, Candiani G, Romanó G, Brunati C, Riva S, Cavaleri M.

Antimicrob Agents Chemother. 2004 Apr;48(4):1118-23.

24.

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.

Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, Mroszczak EJ, Campbell KC, Kelly E.

Antimicrob Agents Chemother. 2004 Mar;48(3):940-5.

25.

European survey of vancomycin-resistant enterococci in at-risk hospital wards and in vitro susceptibility testing of ramoplanin against these isolates.

Goossens H, Jabes D, Rossi R, Lammens C, Privitera G, Courvalin P.

J Antimicrob Chemother. 2003 Jun;51 Suppl 3:iii5-12.

PMID:
12801937
26.

An investigation of the pharmacokinetics and autoinduction of rifabutin metabolism in mice treated with 10 mg/kg/day six times a week for 8 weeks.

Strolin Benedetti M, Pianezzola E, Brianceschi G, Jabes D, Della Bruna C, Rocchetti M, Poggesi I.

J Antimicrob Chemother. 1995 Jul;36(1):247-51.

PMID:
8537275
27.

In-vitro and in-vivo activity of rifabutin against Toxoplasma gondii.

Olliaro P, Gorini G, Jabes D, Regazzetti A, Rossi R, Marchetti A, Tinelli C, Della Bruna C.

J Antimicrob Chemother. 1994 Nov;34(5):649-57.

PMID:
7706160
28.

Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.

Jabès D, Della Bruna C, Rossi R, Olliaro P.

Antimicrob Agents Chemother. 1994 Oct;38(10):2346-50.

29.

Synthesis and biological properties of FCE 25199, a new oral penem.

Alpegiani M, Bedeschi A, Zarini F, Della Bruna C, Jabes D, Perrone E, Franceschi G.

J Antibiot (Tokyo). 1992 May;45(5):797-801. No abstract available.

30.

Dual-action penems.

Perrone E, Jabés D, Alpegiani M, Andreini BP, Della Bruna C, Del Nero S, Rossi R, Visentin G, Zarini F, Franceschi G.

J Antibiot (Tokyo). 1992 Apr;45(4):589-94. No abstract available.

31.

Synthesis and structure-activity relations in the class of 2-(pyridyl)penems.

Bedeschi A, Visentin G, Perrone E, Giudici F, Zarini F, Franceschi G, Meinardi G, Castellani P, Jabes D, Rossi R, et al.

J Antibiot (Tokyo). 1990 Mar;43(3):306-13.

32.
33.

Lytic and bactericidal activity of FCE 22101.

Jabes D, Tomasz A.

J Antimicrob Chemother. 1989 Mar;23 Suppl C:75-83.

PMID:
2659573
34.

FCE 22101 and FCE 22891: in-vitro antibacterial activity at concentrations simulating human plasma levels following intravenous, intramuscular and oral administration.

Della Bruna C, Jabes D, Rossi R, Younes G, Castellani P.

J Antimicrob Chemother. 1989 Mar;23 Suppl C:119-28.

PMID:
2659570
35.
36.

Novel quaternary ammonium penems: the [(pyridinio)methyl]-phenyl derivatives.

Perrone E, Alpegiani M, Bedeschi A, Giudici F, Zarini F, Franceschi G, Della Bruna C, Jabes D, Meinardi G.

J Antibiot (Tokyo). 1987 Nov;40(11):1636-9. No abstract available.

37.

2-(quaternary ammonio)-methyl penems.

Perrone E, Alpegiani M, Bedeschi A, Giudici F, Zarini F, Franceschi G, Della Bruna C, Jabes D, Meinardi G.

J Antibiot (Tokyo). 1986 Sep;39(9):1351-5. No abstract available.

38.

LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies.

Della Bruna C, Schioppacassi G, Ungheri D, Jabès D, Morvillo E, Sanfilippo A.

J Antibiot (Tokyo). 1983 Nov;36(11):1502-6.

39.

In vitro and in vivo evaluation of the penem FCE 22101 and its orally absorbed ester FCE 22891.

Bruna CD, Jabes D, Sebben G, Sanfilippo A.

G Ital Chemioter. 1983 May-Dec;30(2-3):125-30. No abstract available.

PMID:
6329870
40.

Biological activity of (5R,6S,8R)-6-alpha-hydroxyethyl-2-acetoxymethyl-2-penem-3-carboxylate.

Sanfilippo A, Della Bruna C, Jabes D, Morvillo E, Schioppacassi G, Franceschi G, Arcamone F, Battistini C, Foglio M, Zarini F.

J Antibiot (Tokyo). 1982 Sep;35(9):1248-51. No abstract available.

Supplemental Content

Support Center